BioSpace News Archive

Humana Inc., one of the nation’s leading health and well-being companies, announced the Medicare Star Ratings for its Medicare Advantage plans, effective Jan. 1, 2023, from the Centers for Medicare and Medicaid Services.

BridgeBio will host an investor call on October 17, 2022 at 1:30 pm ET to discuss the data and next steps for its two lead RAS programs.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will share new data from across its genetic medicine portfolio at the 27th International Hybrid Annual Congress of the World Muscle Society 2022 Congress (WMS 2022), taking place Oct. 11-15, 2022, in Halifax, Nova Scotia, Canada.

mRNA Victoria announces that the developers of the Pfizer/BioNTech COVID-19 mRNA vaccine will also establish an Asia-Pacific mRNA clinical research and development centre, enabling Victorian and Australian researchers to advance the next generation of transformative mRNA vaccines and therapies by partnering on scientific mentoring, business development advice and drug design.

Aditxt, Inc.’s AditxtScore™ is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19.

BioSig Technologies, Inc. an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, announced that San Antonio Methodist Hospital has acquired the PURE EP™ System.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or the “Company”) is pleased to announce that its non-brokered private placement of convertible notes (the “Notes”) previously announced of up to $6,300,000 CAD has been oversubscribed and has now been increased to up to $10,000,000 CAD in order to further accelerate VINIA® sales growth and Cannabis commercialization activities in North America.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) pursuant to the terms of the Company’s Stock Option Plan.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) pursuant to the terms of the Company’s Stock Option Plan.